We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-0.8%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$210M
AUM Growth
+$27M
(+15%)
Cap. Flow
+$36.3M
Cap. Flow
% of AUM
17.25%
Top 10 Holdings %
Top 10 Hldgs %
68.42%
Holding
39
New
7
Increased
15
Reduced
3
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dentsply Sirona
XRAY
|
+$13.8M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$9.65M |
| 3 |
SRCL
Stericycle Inc
SRCL
|
+$9.37M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
+$7.59M |
| 5 |
VSI
Vitamin Shoppe Inc.
VSI
|
+$4.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pacira BioSciences
PCRX
|
+$6.99M |
| 2 |
Nektar Therapeutics
NKTR
|
+$6.27M |
| 3 |
Labcorp
LH
|
+$5.64M |
| 4 |
Quest Diagnostics
DGX
|
+$4.92M |
| 5 |
QuidelOrtho
QDEL
|
+$4.89M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.05% |
| 2 | Industrials | 5.57% |
| 3 | Consumer Discretionary | 4.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
NovoCure
NVCR
$2.09B
| $24.3M | 11.56% |
1,115,000
+60,000
| +6% | +$1.29M |
|
|
NUVA
2
DELISTED
NuVasive, Inc.
NUVA
| $18.8M | 8.94% |
360,000
+149,660
| +71% | +$7.59M |
|
|
MDRX
3
DELISTED
Veradigm Inc. Common Stock
MDRX
| $18.2M | 8.66% |
1,475,000
+100,000
| +7% | +$1.42M |
|
4
Medtronic
MDT
$120B
| $15.2M | 7.25% |
190,000
+40,000
| +27% | +$3.3M |
|
|
CORI
5
DELISTED
Corium International, Inc.
CORI
| $12.7M | 6.03% |
1,105,000
+95,000
| +9% | +$1.15M |
|
6
Gilead Sciences
GILD
$187B
| $12.4M | 5.92% |
165,000
+35,000
| +27% | +$2.78M |
|
|
7
Dentsply Sirona
XRAY
$2.27B
| $11.8M | 5.62% |
+235,000
| New | +$13.8M |
|
|
SRCL
8
DELISTED
Stericycle Inc
SRCL
| $11.7M | 5.57% |
200,000
+138,359
| +224% | +$9.37M |
|
|
9
Bio-Rad Laboratories Class A
BIO
$10.3B
| $9.48M | 4.51% |
+37,900
| New | +$9.65M |
|
|
NXTM
10
DELISTED
NxStage Medical Inc.
NXTM
| $9.15M | 4.35% |
368,260
+93,260
| +34% | +$2.27M |
|
|
11
QuidelOrtho
QDEL
$958M
| $8.55M | 4.07% |
165,000
-105,000
| -39% | -$4.89M |
|
|
12
Labcorp
LH
$26.5B
| $7.6M | 3.62% |
54,708
-38,412
| -41% | -$5.64M |
|
13
Alkermes
ALKS
$7.73B
| $6.38M | 3.03% |
110,000
+40,000
| +57% | +$2.34M |
|
|
VSI
14
DELISTED
Vitamin Shoppe Inc.
VSI
| $4.87M | 2.32% |
+1,119,559
| New | +$4.88M |
|
|
CORV
15
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $4.35M | 2.07% |
1,875,000
| – | – |
|
16
Service Corp International
SCI
$11.2B
| $4.34M | 2.06% |
115,000
+15,000
| +15% | +$576K |
|
17
Steris
STE
$21.9B
| $4.2M | 2% |
45,000
+20,000
| +80% | +$1.82M |
|
18
AtriCure
ATRC
$2.62B
| $4.13M | 1.96% |
201,000
+26,000
| +15% | +$470K |
|
|
19
Pacira BioSciences
PCRX
$1.05B
| $3.7M | 1.76% |
118,702
-196,298
| -62% | -$6.99M |
|
20
Lantheus
LNTH
$6.59B
| $3.43M | 1.63% |
215,558
+65,121
| +43% | +$1.27M |
|
|
HOLX
21
DELISTED
Hologic
HOLX
| $2.8M | 1.33% |
+75,000
| New | +$3.03M |
|
|
CERN
22
DELISTED
Cerner Corp
CERN
| $2.61M | 1.24% |
+45,000
| New | +$2.92M |
|
|
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.33M | 1.11% |
848,840
+98,840
| +13% | +$287K |
|
|
STRM
24
DELISTED
Streamline Health Solutions
STRM
| $2.02M | 0.96% |
73,114
+3,114
| +4% | +$80.7K |
|
|
LMNX
25
DELISTED
Luminex Corp
LMNX
| $2M | 0.95% |
+94,757
| New | +$1.94M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q1 2018 Portfolio in Review
As of Q1 2018, Tamarack Advisers held 39 positions worth $210M, up 15% from $183M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Tamarack Advisers deployed $36.3M of net new capital in Q1 2018, opening 7 new positions and adding to 15 existing holdings. Its largest new stake was Dentsply Sirona: 235,000 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Pacira BioSciences, an estimated $6.99M trimmed.
- Tamarack Advisers's largest Q1 2018 buy was Dentsply Sirona: 235,000 shares worth $11.8M.
- Tamarack Advisers added most to Stericycle Inc in Q1 2018, an estimated $9.37M increase.
- Tamarack Advisers's biggest Q1 2018 reduction was Pacira BioSciences, cutting an estimated $6.99M.
- Tamarack Advisers fully exited Nektar Therapeutics in Q1 2018, selling an estimated $6.27M.
- Tamarack Advisers's ten largest holdings make up 68% of its $210M portfolio in Q1 2018.
- Tamarack Advisers opened 7 new positions and closed 12 in Q1 2018.
- Tamarack Advisers's portfolio value rose 15% quarter-over-quarter to $210M.
Based on Tamarack Advisers's 13F filing for Q1 2018, filed 8 May 2018.